Drug intelligence / Profile preview

Synovitis Granules

Development stage: Unknown
Lead developer: Shijiazhuang Third Hospital
Modality: Small Molecules
Administration: Oral

Overview

Synovitis Granules is an experimental multi-ingredient pharmaceutical drug, likely a Traditional Chinese Medicine (TCM) formulation, being investigated for the treatment of knee osteoarthritis. It is believed to exert its therapeutic effects by inhibiting inflammation and bone cell fibrosis, potentially through the suppression of the SDF-1/CXCR4 signaling pathway, leading to reduced expression of SDF-1, CXCR4, MMP-9, and MMP-13. This mechanism suggests anti-inflammatory and cartilage-protective properties.

Targets

CXCL12 (C-X-C motif chemokine ligand 12)CXCR4 (C-X-C motif chemokine receptor 4)

Beyond the preview

Go deeper on Synovitis Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synovitis Granules.

Explore the full profile